Oncology Central

Scientific and regulatory challenges in development of CAR-T therapy for solid tumors

In this interview with Stephen Gottschalk from St. Jude Children’s Research Hospital (TN, USA) discover some of the challenges in developing CAR-T therapies for solid tumors, major milestones in their development and where the field is heading.
Could you give us a brief outline of the talk you recently presented at AACR 2018?

I presented at American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA) in a session titled “Scientific and Regulatory Challenges in Development of CAR-T Therapy for Solid Tumors,” which was organized by Ke Liu from the US FDA. Carl June presented data from his clinical studies targeting mesothelin with CAR-T cells for pancreatic cancer, and Behnam Badie presented the results of clinical studies using IL13Ra2-specific CAR-T cells for high-grade glioma. Gary Archer focused on the evaluation of CAR-T cells in preclinical glioma models and I described the outcome of our clinical studies with HER2-CAR-T cells for sarcoma and high-grade glioma. At the end, Peter Boss reviewed the current status of CAR INDs and CAR protocols from an FDA perspective.

What are some of the challenges in developing CAR-T therapies for solid tumors?
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.





News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.